Palliative radiotherapy in symptomatic pelvic soft tissue tumors (PallSoft)- protocol for a national, randomized, non-inferiority study.
Kjersti Skipar, Maren S Ørvik, Christoph Evers...
https://pubmed.ncbi.nlm.nih.gov/40597814/Actively Recruiting
Led by Sykehuset Telemark · Updated on 2025-05-23
200
Participants Needed
11
Research Sites
52 weeks
Total Duration
Researchers are investigating palliative radiotherapy for patients with symptomatic pelvic soft tissue tumors from gastrointestinal, urological, or gynecological cancers. This national, randomized, open-label phase III trial aims to determine if a short-course radiotherapy schedule 1-2 fractions of 8 Gy provides symptom relief that is not worse than a longer schedule 5 fractions of 5 Gy. The study also evaluates health-related quality of life, toxicities, survival, and biomarkers related to tumor hypoxia as secondary and exploratory goals. Participants will receive either a short-course radiotherapy treatment of 8 Gy in 1-2 sessions or a longer course of 5 Gy in 5 sessions. Both schedules are delivered as palliative care to relieve symptoms such as pain, bleeding, or dysfunction in bowel, urinary, or vaginal areas. Patients will choose a main symptom to track during the study. The trial specifically excludes curative treatments and focuses on symptom control with radiation therapy. During the study, patients are monitored through patient-reported symptom intensity assessments, physician-reported toxicities up to 52 weeks, and survival evaluations over two years. Researchers will also collect quality of life data and explore biomarkers to better understand treatment effects. Participation involves regular symptom reporting and clinical follow-up, with the primary outcome measured 12 weeks after treatment.
CONDITIONS
Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors
K
Kjersti Skipar, MD
H
Harald Ragnum, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sykehuset Telemark
Lead Sponsor
Nordlandssykehuset HF
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 to 2 weeks
Participants receive palliative radiotherapy with either 1-2 fractions of 8 Gy or 5 fractions of 5 Gy to relieve symptoms from pelvic soft tissue tumors.
1 to 5 visits depending on radiotherapy schedule
Duration - Up to 2 years
Participants are monitored for symptom relief, toxicities, quality of life, and survival after radiotherapy.
Regular assessments up to 12 weeks for symptom effect and up to 52 weeks for toxicities with survival follow-up to 2 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kjersti Skipar, Maren S Ørvik, Christoph Evers...
https://pubmed.ncbi.nlm.nih.gov/40597814/Sykehuset Telemark
Lead Sponsor
Nordlandssykehuset HF
Collaborating Sponsor